Loading clinical trials...

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE3

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer

NCT07473128•Pharmacosmos A/S

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
•Complete recovery from prior anti-tumor surgical procedures
•Measurable and evaluable disease through tumor assessment
•Willingness to participate and sign informed consent form

Exclusion Criteria

•Extensive Stage Small Cell Lung Cancer
•Active cardiovascular disease
•Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
•Pregnant or nursing women

Key Dates

Start Date

March 31, 2026

Primary Completion Date

June 1, 2027

Completion Date

June 1, 2027

Last Updated

March 16, 2026

Enrollment

120

ESTIMATED participants

Conditions

Limited Stage Small Cell Lung Cancer

Interventions

Trilaciclib

DRUG

Saline (0.9% NaCl)

DRUG

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774

Limited Stage Small Cell Lung CancerSmall Cell Lung Cancer

View study

RECRUITINGPHASE2

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

NCT05443646

Limited Stage Small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease